Your browser doesn't support javascript.
loading
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Chi, Kim N; Higano, Celestia S; Blumenstein, Brent; Ferrero, Jean-Marc; Reeves, James; Feyerabend, Susan; Gravis, Gwenaelle; Merseburger, Axel S; Stenzl, Arnulf; Bergman, Andries M; Mukherjee, Som D; Zalewski, Pawel; Saad, Fred; Jacobs, Cindy; Gleave, Martin; de Bono, Johann S.
Afiliação
  • Chi KN; Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada. Electronic address: kchi@bccancer.bc.ca.
  • Higano CS; Department of Medicine, Division of Medical Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Blumenstein B; Trial Architecture Consulting, Washington, DC, USA.
  • Ferrero JM; Centre Antoine Lacassagne, Nice, France.
  • Reeves J; Florida Cancer Specialists, Fort Myers, FL, USA.
  • Feyerabend S; Department of Urology, Tübingen, Germany.
  • Gravis G; Institut Paoli Calmette, Department of Cancer Medicine, Marseille, France.
  • Merseburger AS; Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
  • Stenzl A; University of Tübingen, Tübingen, Germany.
  • Bergman AM; Netherlands Cancer Institute and Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
  • Mukherjee SD; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON, Canada.
  • Zalewski P; Durham Regional Cancer Centre, Oshawa, ON, Canada.
  • Saad F; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Jacobs C; OncoGenex Pharmaceuticals, Bothell, WA, USA.
  • Gleave M; Department of Medicine, Division of Medical Oncology, University of British Columbia, BC Cancer Agency, Vancouver Prostate Centre, Vancouver, BC, Canada.
  • de Bono JS; Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, London, UK.
Lancet Oncol ; 18(4): 473-485, 2017 04.
Article em En | MEDLINE | ID: mdl-28283282
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias de Próstata Resistentes à Castração Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Aged80 / Humans / Male / Middle aged Idioma: En Ano de publicação: 2017 Tipo de documento: Article